FIELD: medicine.
SUBSTANCE: what is presented is a vector for independent expression of at least two nucleic acid molecules which codes the same or different polypeptides of closely related human papilloma virus (HPV) serotypes and naturally contains the sequences having an identity of max. 80% on sites of the length of min. 40 sequential nucleotides. The invention also refers to a host cell containing the presented vector construct for multiple expression of HPV polypeptides, as well as to pharmaceutical compositions for prevention and therapy of the conditions caused by papilloma virus infection containing the vector or the vector-transformed host cells.
EFFECT: if involved in the vector, said molecules are modified so that to reduce percentage of identity of the sequences and reducing size of homology sites to the number of sequential nucleotides max 8.
32 cl, 4 dwg, 5 ex
Title | Year | Author | Number |
---|---|---|---|
PAPILLOMAVIRUS E2 POLYPEPTIDES USED FOR VACCINATION | 2008 |
|
RU2482189C2 |
AVIAN TELOMERASE REVERSE TRANSCRIPTASE | 2007 |
|
RU2415867C2 |
EXPRESSING VECTOR (VARIANTS) | 1995 |
|
RU2177999C2 |
IMMORTALISED CELL LINE OF BIRDS | 2008 |
|
RU2475536C2 |
MUTANT POLYMERASES OF HEPATITIS B VIRUS | 2012 |
|
RU2625021C2 |
VACCINES AGAINST HPV | 2012 |
|
RU2644201C2 |
VACCINE COMPOSITION | 2014 |
|
RU2684211C2 |
RECOMBINANT VIRAL VACCINE | 2007 |
|
RU2453335C2 |
COMPOSITION FOR TREATMENT OF CANCER ASSOCIATED WITH HPV INFECTION | 2013 |
|
RU2636003C2 |
HYBRIDISATION OF HETEROOLIGOMER MYCOBACTERIAL ANTIGENS | 2015 |
|
RU2695462C2 |
Authors
Dates
2012-09-27—Published
2008-01-29—Filed